Janice Robertson, University of Toronto WS 6.1.1 Genetic Aspects of ALS Overlap Syndromes 15:30 – 16:15 |
Maria Carmela Tartaglia, Centre for Research in Neurodegenerative Diseases WS 6.1.2 Clinical Aspects of ALS Overlap Syndromes 16:15 – 17:00 |
WS 5.1.1 – The Clinicians Approach to Muscular Dystrophies
Volker Straub, Newcastle University LGMDs 13:30 – 14:15 |
Carsten G. Bonnemann, National Institute of Neurological Disorders and Stroke/NIH Porter Neuroscience Research Center Congenital Muscular Dystrophies 14:15 – 15:00
|
Luis Querol, Hospital Sant Pau. Universitat Autònoma Barcelona WS 7.1.1 IgG4 Autoantibodies Related to Neuromuscular Diseases: Therapeutic Implications 13:30 – 14:15 |
Andrew Mammen, National Institutes of Health WS 7.1.2 Is It All About the Antibodies 14:15 – 15:00 |
Alexander Sherman, Massachusetts General Hospital WS 4.1.1 Technology Platforms for Clinical Research 15:30 – 16:15 |
Jon Katz, California Pacific Medical Center WS 4.1.2 Using the Electronic Medical Record for Research 16:15 – 17:00 |
Richard Barohn, University of Kansas Medical Center WS 3.1.1 Challenges for Investigator Initiated Trials and for Conducting Multicenter Trials 13:30 – 14:15 |
Richard Barohn, University of Kansas Medical Center WS 3.1.2 Transatlantic Challenges 14:15 – 15:00 |
Anthony Arnold Amato, Brigham and Women’s Hospital WS 4.2.1 Nerve Biopsy Are Rarely Needed 15:30 – 16:15 |
P. James Dyck, Mayo Clinic WS 4.2.2 It Is Valuable 16:15 – 17:00 |
Hans D. Katzberg, University of Toronto WS 6.2.1 Treatment of Muscle Cramps 15:30 – 16:15 |
Nicholas Silvestri, University at Buffalo School of Medicine and Biomedical WS 6.2.2 Assessment of Patients with Muscle Cramps 16:15 – 17:00 |
James Russell, University of Maryland School of Medicine WS 6.3.1 Epidemiology and Pathophysiology of Diabetic Neuropathy 15:30 – 16:15 |
Vera Bril, University of Toronto WS 6.3.2 Treatment of Diabetic Neuropathy 16:15 – 17:00 |
Bruce Perkins, Mount Sinai Hospital WS 5.3.1 Diagnosis of DSP 13:30 – 14:15 |
Evan Lewis, University of Toronto WS 5.3.2 Omega 3 Oil & Results in the Study 14:15 – 15:00 |
Charles Thornton, University of Rochester Medical Center, School of Medicine and Dentistry WS 3.2.1 How to Treat Myotonic Dystrophy 13:30 – 14:15 |
Richard T. Moxley, III, University of Rochester Medical Center WS 3.2.2 Current Knowledge About Myotonic Dystrophy 14:15 – 15:00 |
Panel Discussion
16:30 – 17:00
Michael G. Fehlings, University of Toronto WS 2.1.1 Emerging Concepts in the Pathobiology of Degenerative Cervical Myelopathy, Epidemiology and Clinical Presentation 15:30 – 15:45 |
Anthony Burns, University Health Network – Toronto Rehabilitation Institute WS 2.1.2 Clinical Implications, Outcomes and Rehabilitation Pathways 15:45 – 16:00 |
Sukhvinder Kalsi-Ryan, University Health Network WS 2.1.3 Understanding Disease Severity Through Novel Surrogate Measurement Approaches in NTSCI 16:00 – 16:15 |
Julien Cohen-Adad, Ecole Polytechnique, Université de Montréal WS 2.1.4 Advanced Techniques in Imaging Specific to Degenerative Myelopathy 16:15 – 16:30 |
Mary Reilly, National Hospital for Neurology and Neurosurgery and ION WS 7.2.1 Nerve 13:30 – 14:15 |
Raveen Basran, The Hospital for Sick Children (SickKids) WS 7.2.2 Muscle 14:15 – 15:00 |
Ronni Haller, University of Texas Southwestern Medical School WS 8.1.1 Exercise Therapy in Mitochondrial Disorders 15:30 – 16:15 |
John Vissing, Rigshospitalet, University of Copenhagen WS 8.1.2 Exercise Training and Pathophysiology of Exercise in Metabolic Myopathies 16:15 – 17:00 |
Stephan Züchner, University of Miami Miller School of Medicine WS 4.3.1 Overview of Genetics of Hereditary Polyneuropathy 15:30 – 16:15 |
Mario Saporta, University of Miami WS 4.3.2 Cellular Reprogramming and Inherited Peripheral Neuropathies: Perspectives and Challenges 16:15 – 17:00 |
Richard Barohn, University of Kansas Medical Center WS 8.2.1 Why Patient-Centered Outcomes Research? 15:30 – 16:15 |
Richard Barohn, University of Kansas Medical Center WS 8.2.2 Investigator-Initiated Clinical Trials 16:15 – 17:00 |
Carsten G. Bonnemann, National Institute of Neurological Disorders and Stroke/NIH Porter Neuroscience Research Center WS 1.1.1 Muscle Ultrasound 13:30 – 14:15 |
Volker Straub, Newcastle University WS 1.1.2 The Application of MRI in Muscle Disease 14:15 – 15:00 |
Mazen Dimachkie, University of Kansas Medical Center WS 7.3.1 General Treatment Approaches 13:30 – 14:15 |
Anthony Arnold Amato, Brigham and Women’s Hospital WS 7.3.2 Ongoing Developments in IBM 14:15 – 15:00 |
WS 5.2.1 – Interesting Neuromuscular Cases moderated by Dr. Katzberg & Dr. Izenberg
Hans D. Katzberg, University of Toronto |
Aaron Izenberg, University of Toronto |
Stacy Rudnicki, Cytokinetics WS 1.2.1 Symptomatic Treatment of ALS 13:30 – 14:15 |
Christen Shoesmith, London Health Sciences Centre University Hospital WS 1.2.2 End of Life Issues in ALS 14:15 – 15:00 |
Mark Tarnopolsky, McMaster University WS 1.3.1 Evaluation and Treatment of Pompe Disease 13:30 – 14:15 |
John Vissing, Rigshospitalet, University of Copenhagen WS 1.3.2 Dietary and Other Therapies in Muscle Glycogenoses and Disorders of Muscle Lipid Oxidation 14:15 – 15:00 |
A. Gordon Smith, University of Utah WS 8.3.1 Neuropathy in Pre-Diabetes & The Metabolic Syndrome 15:30 – 16:15 |
Mamatha Pasnoor, The University of Kansas Medical Center WS 8.3.2 Neuropathies in Systemic Disease 16:15 – 17:00 |
Grace Yoon, Hospital for Sick Children (SickKids) WS 3.3.1 What is New in Genetics 13:30 – 14:15 |
Kevin Flanigan, Nationwide Children’s Hospital WS 3.3.2 TBC 14:15 – 14:00 |
Susan Iannaccone, University of Texas Southwestern Medical Center WS 7.4.1 SMA Today 13:30 – 14:15 |
John Kissel, The Ohio State University Wexner Medical Center WS 7.4.2 Update on SMA 14:15 – 15:00 |
Jennifer Kollmer, University of Heidelberg WS 2.2.1 Novel Processing Methods for Peripheral Nerve Imaging 15:30 – 16:15 |
Ali Naraghi, Toronto Western Hospital, University Health Network WS 2.2.2 Challenges in MRI Studies of Peripheral Nerves 16:15 – 17:00 |
Lawrence Korngut, University of Calgary, Clinical Neurosciences WS 1.4.1 Neuromuscular Databases 13:30 – 14:15 |
TBC WS 1.4.2 Treat NMD 14:15 – 15:00 |
John D. England, LSUHSC School of Medicine WS 5.4.1 The Role of Guidelines in Decisions on Treatment 13:30 – 14:15 |
Jaya Trivedi, UT Southwestern Medical Center WS 5.4.2 Update on Treatment of Neuropathic Pain 14:15 – 15:00 |
Ingemar Merkies, Academic Hospital Maastricht WS 4.1.1 What the Perinoms Study Taught Us 15:30 – 16:15 |
Jean-Marc Léger, CHU Pitié Salpêtrière WS 4.4.2 How We Should Assess Inflammatory 16:15 – 17:00 |
Linda Lowes, Nationwide Children’s Hospital WS 8.4.1 Best Outcome Measures to Use for NM Patients/strong> 15:30 – 16:15 |
Craig McDonald, Center for Healthcare Policy and Research, UC Davis Children’s Hospital WS 8.4.2 Outcome Measures in Muscular Dystrophy 16:15 – 17:00 |
Carolina Barnett Tapia, University of Toronto WS 5.5.1 Myasthenia Gravis Impairment Index 13:30 – 14:15 |
Ted Burns, University of Virginia School of Medicine WS 5.5.2 Review of Current MG Scales 14:15 – 15:00 |
Mary Reilly, National Hospital for Neurology and Neurosurgery and ION WS 2.3.1 Outcomes in CMT 15:30 – 16:15 |
Michael Shy, University of Iowa WS 2.3.2 Monitoring Hereditary Neuropathies in Clinical Trials 16:15 – 17:00 |
Wolfgang Grisold, Vienna Hospital Association WS 6.4.1 Lymphoma and Other Peripheral Nerve Tumors 15:30 – 16:15 |
Gelareh Zadeh, University Health Network WS 6.4.2 Neurofibromatosis 1 and Malignant Transformation of Peripheral Nerve Sheath Tumors 16:15 – 17:00 |
Mary Reilly, National Hospital for Neurology and Neurosurgery and ION WS 4.5.1 Evaluation of Variants of Unknown Significance 15:30 – 16:15 |
Livija Medne, The Children’s Hospital of Philadelphia WS 4.5.2 Clinical Whole Exome Sequencing 16:15 – 16:25 |
Kim Amburgey, Hospital for Sick Children WS 4.5.2 Gene Panels 16:25 – 16:45 |
Joint Discussion 16:45 – 17:00 |
Eva Feldman, 15:30 – 16:15 |
Michael James Polydefkis, Johns Hopkins Bayview Medical Center WS 2.4.2 Role of Skin Punch Biopsy As a Research Outcome Measure 16:15 – 17:00 |
David Adams, CHU Bicêtre, APHP, Univ Paris Sud, FILNEMUS WS 3.4.1 Amyloid Neuropathy as a Model of Small Fiber Neuropathy 13:30 – 14:15 |
Giuseppe Lauria, Fondazione I.R.C.C.S Istituto Neurologico Carlo Besta WS 3.4.2 Diagnosis of Small Fibre Neuropathy 14:15 – 15:00 |
Kevin Flanigan, Nationwide Children’s Hospital WS 8.5.1 Gene-Directed Treatment of Muscular Dystrophy 15:30 – 16:15 |
Francesco Muntoni, UCL Institute of Child Health WS 8.5.2 Non-Gene Directed 16:15 – 17:00 |
Gil I. Wolfe, University at Buffalo/SUNY School of Medicine and Biomedical Sciences WS 1.5.1 General Treatment Approaches 13:30 – 14:15 |
Susan Iannaccone, University of Texas Southwestern Medical Center WS 1.5.2 Treatment of MG in the Paediatric Population 14:15 – 15:00 |
Francis O. Walker, Wake Forest Baptist Health Neurology WS 3.5.1 Practical Demonstration and Discussion 13:30 – 15:00 |
Francis O. Walker, Wake Forest Baptist Health Neurology WS 2.5.1 Practical Demonstration and Discussion 15:30 – 17:00 |
Steven Shook, Cleveland Clinic WS 6.5.1 Neuromuscular Physicians Should Perform NM Ultrasound 15:30 – 16:15 |
Linda Probyn, University of Toronto WS 6.5.2 Radiologists Should Perform NM Ultrasound 16:15 – 17:00 |
Rabi Tawil, University of Rochester Medical Center WS 7.5.1 Recent Concepts in FSHD 13:30 – 14:15 |
Jeffrey M. Statland, University of Kansas Medical Center WS 7.5.2 Clinical Presentation in FSHD 14:15 – 15:00 |